Stilla Technologies is a leading global biotechnology company that focuses on accelerating the development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The NAICA® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR platform, providing high multiplexing and sensitivity for advancing cancer and liquid biopsy studies, cell and gene therapies, infectious disease and COVID-19 research, and wastewater and environmental testing, among many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.
Is this your company?
Something looks off?
On-site & Remote
